title: [Investigation of gemcitabine plus lomustine treatment in mice with transplantable lymphosarcoma LIO-1].
abstract: Efficiency of gemcitabine plus lomustine treatment of transplantable lymphosarcoma LIO-1 in mice was significantly higher than that of monotherapy. According to the area under the kinetic curve for tumor growth, antitumor action, for single maximum tolerable dose of gemcitabine 25 mg/kg body, rose 4.6 times (p < or = 0.001), for lomustine 50 mg/kg body,--2.9 times (p < or = 0.01). The combination involved moderately increased toxicity. Lethality rate for gemcitabine+lomustine, 50 mg/kg body each, was as low as one and a half times as compared with gemcitabine therapy alone, 50 mg/kg body, (30 and 20%, respectively). The antitumor action of the combination (50 mg/kg body), was 32 times that of gemcitabine 50 mg/kg body (p < or = 0.001) and lomustine 50 mg/kg body--30 times (p < or = 0.001).
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: A A
authors.initials: AA
authors.lastname: Tarasenkova
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: L V
authors.initials: LV
authors.lastname: Filatova
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Semiglazova
authors.forename: D Kh
authors.initials: DKh
authors.lastname: Latipova
authors.forename: S F
authors.initials: SF
authors.lastname: Vershinina
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D019540:Area Under Curve; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D008130:Lomustine / Q000008:administration & dosage / Q000009:adverse effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D011897:Random Allocation; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003841:Deoxycytidine; D008130:Lomustine; D000093542:Gemcitabine